What Is Vitamin D Level Testing

Vitamin D level testing is a blood test that measures the concentration of 25-hydroxyvitamin D (calcidiol) to assess whether the body maintains sufficient stores of this fat-soluble secosteroid. The test is typically performed via a simple venous blood draw or, in some at-home kits, a finger-prick dried blood spot. It serves as the standard clinical method for identifying deficiency, insufficiency, or excess of vitamin D.

Vitamin D functions less like a classic vitamin and more like a hormone precursor, influencing the expression of several hundred genes involved in calcium metabolism, immune regulation, cellular proliferation, and neuromuscular function. Deficiency is associated with reduced bone mineral density, increased fracture risk, impaired immune defense, and correlations with cardiovascular disease and certain cancers. Because symptoms of low vitamin D are often subtle or nonexistent until deficiency becomes severe, blood testing is the only reliable way to know where someone stands.

From a longevity perspective, maintaining adequate vitamin D status supports the structural integrity of the skeleton across decades, preserves muscle function that prevents falls in later life, and modulates inflammatory pathways implicated in age-related disease. Populations at higher risk of deficiency include those living at northern latitudes, individuals with darker skin pigmentation, people who spend little time outdoors, older adults whose skin synthesizes vitamin D less efficiently, and those with obesity (vitamin D is sequestered in adipose tissue). Testing transforms vitamin D management from guesswork into a data-informed practice.

The test measures 25-hydroxyvitamin D, the form produced when the liver hydroxylates vitamin D3 (cholecalciferol, from sun or animal sources) or vitamin D2 (ergocalciferol, from plant or fungal sources). This metabolite circulates bound to vitamin D binding protein and has a half-life of roughly two to three weeks, making it a stable marker of cumulative vitamin D status rather than a snapshot of a single day's intake or exposure.

Most clinical laboratories use either immunoassay or liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify 25-hydroxyvitamin D. LC-MS/MS is considered the reference method because it can separately quantify D2 and D3 forms with higher accuracy, while immunoassays are more widely available and less expensive. The distinction matters when a person supplements with D2, because some immunoassays undercount that form. Results are reported in nanograms per milliliter (ng/mL) in the United States or nanomoles per liter (nmol/L) internationally, with 1 ng/mL equaling 2.5 nmol/L.

The test does not measure 1,25-dihydroxyvitamin D (calcitriol), the hormonally active form produced in the kidneys. Calcitriol has a short half-life and is tightly regulated by parathyroid hormone, calcium, and phosphate levels, so it can appear normal even when vitamin D stores are depleted. Ordering calcitriol instead of calcidiol is a common clinical error that can mask true deficiency. Some practitioners order both markers in specific clinical scenarios involving granulomatous diseases or kidney disorders, but for routine screening, 25-hydroxyvitamin D alone is the appropriate test.

The vitamin D test measures serum 25-hydroxyvitamin D, also called calcidiol or 25(OH)D. This is the primary circulating form of vitamin D and the metabolite that best reflects total body stores accumulated from ultraviolet B exposure, dietary intake, and supplementation. The liver converts both vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol) into their respective 25-hydroxylated forms, and the test captures both unless a method-specific assay is used.

Some advanced assays separately quantify 25(OH)D2 and 25(OH)D3, which can be useful for clinicians who want to distinguish between supplemental D2 and endogenous or supplemental D3 contributions. A related but distinct marker, 1,25-dihydroxyvitamin D (calcitriol), measures the hormonally active form produced primarily in the kidneys. This marker is not appropriate for routine screening because it is tightly regulated and may remain normal even in the face of depleted stores. Ordering the wrong test is a common clinical mistake, so confirming that the order specifies 25-hydroxyvitamin D is important.

No fasting is required for a 25-hydroxyvitamin D blood test. The metabolite reflects cumulative status over weeks, so eating or drinking before the draw does not alter the result. If the test is part of a broader panel that includes fasting-dependent markers like glucose or triglycerides, follow the fasting instructions for the overall panel.

There is no need to stop vitamin D supplementation before testing; the purpose of the test is to evaluate your level under your current regimen. However, note when your last dose was taken for context when reviewing results with a clinician. If using an at-home finger-prick kit, follow the collection instructions carefully, as inadequate blood volume on a dried blood spot card can lead to unreliable results. Morning collection is generally preferred for consistency across serial tests, though it is not strictly required.

Results are typically reported in ng/mL (United States) or nmol/L (most other countries), with the conversion being 1 ng/mL equals 2.5 nmol/L. The Endocrine Society classifies levels below 20 ng/mL as deficient, 20 to 29 ng/mL as insufficient, and 30 to 100 ng/mL as sufficient. The Institute of Medicine uses a lower threshold of 20 ng/mL for sufficiency based on bone health endpoints.

Many practitioners in functional and longevity medicine aim for a range of 40 to 60 ng/mL, citing observational associations with improved immune function and reduced chronic disease risk, though this target is not universally endorsed by major guidelines. Levels above 100 ng/mL are considered potentially toxic, and levels above 150 ng/mL are associated with overt hypercalcemia. When interpreting results, consider the time of year (winter values are naturally lower), your supplementation dose, body composition, and the assay method used, as immunoassay and LC-MS/MS can yield slightly different numbers for the same sample.

For someone establishing a baseline or initiating supplementation, testing twice in the first year is practical: once in late winter (when levels are lowest) and once in late summer (when they peak). This two-point approach reveals your seasonal range and helps calibrate dosing. After adjusting a supplement dose, wait at least eight to twelve weeks before retesting, because the two-to-three-week half-life of calcidiol means it takes several weeks for a new steady state to be reached.

Once levels are stable within a target range on a consistent regimen, annual testing is generally sufficient. More frequent monitoring (every three to four months) may be appropriate for individuals with malabsorption syndromes, those taking very high doses (above 5,000 IU daily), or patients with conditions where vitamin D metabolism is altered, such as chronic kidney disease or sarcoidosis.

Large epidemiological studies consistently associate low 25-hydroxyvitamin D levels with increased risk of osteoporosis, fractures, respiratory infections, cardiovascular events, and all-cause mortality. Randomized controlled trials have confirmed that supplementation reduces fracture risk in elderly populations when combined with calcium, and a large trial (the VITAL study involving over 25,000 participants) found that vitamin D supplementation did not significantly reduce cancer incidence or major cardiovascular events in a generally vitamin D-replete population, suggesting that benefits are clearest when correcting actual deficiency rather than adding to already-adequate levels.

The optimal target level remains debated. The Institute of Medicine set 20 ng/mL as the threshold for sufficiency based primarily on bone outcomes, while the Endocrine Society recommends at least 30 ng/mL. Some observational data suggest additional benefits at 40 to 60 ng/mL for immune and metabolic outcomes, but randomized trials have not consistently supported superior outcomes at these higher thresholds. Genetic variability in vitamin D metabolism (including polymorphisms in VDR, CYP2R1, CYP27B1, and GC genes) likely explains some of the inconsistency across studies and supports the value of individualized testing over population-level dosing recommendations.

The test itself carries negligible risk, limited to minor discomfort from a blood draw or finger prick. Misinterpretation of results is the primary concern: reacting to a single low reading without considering seasonal variation, recent illness, or assay limitations can lead to inappropriate high-dose supplementation. Prolonged intake pushing levels above 100 ng/mL risks hypercalcemia, nephrolithiasis, and vascular calcification. At-home dried blood spot kits may have wider variability than laboratory venous draws, so clinically important decisions should ideally be confirmed with a standard lab test. Individuals on medications that affect calcium metabolism or those with granulomatous diseases should interpret results with clinical guidance.